title: Treatment of Clostridium difficile colitis. Summary of a round table held in Brussels on March, 3rd, 1994.
abstract: Due to the growing incidence and the severity of infections due to vancomycin resistant enterococci, it is now recommended to treat mild to moderate cases of Clostridium difficile-associated diarrhoea with metronidazole while maintaining the use of oral vancomycin in serious or life-threatening colitis. Clostridium difficile is a common cause of diarrhoea after antibiotic therapy and induces a spectrum of diseases ranging from mild diarrhoea to pseudomembranous colitis (PMC). It is considered to be the first cause of diarrhoea occurring among hospitalized patients (1).
authors.affiliation: Université Catholique de Louvain, Unité de Microbiologie, Bruxelles.
authors.forename: M
authors.initials: M
authors.lastname: Delmée
authors.forename: P
authors.initials: P
authors.lastname: Melin
authors.forename: W
authors.initials: W
authors.lastname: Peetermans
authors.forename: L
authors.initials: L
authors.lastname: Verbist
authors.forename: G
authors.initials: G
authors.lastname: Verschraegen
mesh_terms: D016360:Clostridioides difficile; D003015:Clostridium Infections / Q000188:drug therapy*; D003092:Colitis / Q000188:drug therapy* / Q000382:microbiology*; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use*; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D008795:Metronidazole; D014640:Vancomycin